Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Merck registers two new Phase 1/2 trials; KEYVIBE-005 results remain on recordOct 2Weekly roundup, 8 itemsdolutegravir sodium and lamivudinedoravirineUpdated
Sign inSign in